Advances in Modified & Controlled Release Presented by Catalent Experts at 40th Annual CRS Meeting
Somerset, NJ – July 16, 2013 — Two Catalent experts will present and take part in events at the forthcoming 40th Annual Meeting & Exposition of the Controlled Release Society (CRS), which takes place from July 20-24, 2013.
Ms. Irena McGuffy, Manager Softgel Formulation at Catalent Pharma Solutions, will participate in a workshop, “Overview of Lipids and Lipid-Based Drug Delivery Systems- Selection of Lipid Excipient for Controlling Drug Release,” from 11:30-12:15 on Saturday July 20th. The session will cover the enablement of oral macromolecule delivery using lipid-based drug delivery systems, the modification of drug release through the use of lipid-based fill excipients, and Softgel coating for the purpose of targeted/modified release.
On “CRS Innovation Sunday”, July 21st, Mr. Michael Valazza, VP, Business Development, North America, of Catalent’s newly created Advanced Delivery Technologies business unit, will lead a one hour Technology Forum entitled, “Techniques for Enabling the Delivery of Poorly Soluble Drugs” from 09:00. The forum will consider how the pharmaceutical industry is challenged in progressing development of poorly soluble compounds, and how Zydis® Nano technology, formulation and compression of hot melt extrudates, and other current techniques (softgel, spray dried dispersions), can better enable delivery. Mr. Valazza will be joined by Ms. McGuffy.
From 13:00 to 15:10 the same day, Mr. Valazza will moderate a “Soapbox Session”, giving individuals and companies the opportunity to present new ideas, products, and services. Later he will take part in the roundtable discussion, “Emerging Challenges for Global Delivery- Multiparticulate Oral Drug Delivery Systems for Fixed Dose Combinations,” which takes place from 16:00 to 17:30. The roundtable will consider, the multiparticulate opportunities for fixed dose combinations, including case studies to illustrate challenges and best practices. Mr. Valazza will then present at a focus group, looking at “Multiparticulates in Developing Novel Fixed Dose Combination Products.”
Catalent will also present posters on the following topics during the conference:
- Solid Dispersion Formation of Poorly Soluble Compounds Using OptiMelt™ Hot Melt Extrusion Technology
- Use of ion exchange resin for taste masking cetirizine HCl 10mg formulated in the Zydis dosage form
- Oral mucosal (sub lingual) delivery of vaccines using Zydis orally disintegrating tablets
- Characterizations of Tablets Manufactured by One-Step Dry Coating (OSDrC®) OptiDose™ Technology
Catalent will also exhibit at the event on booths 101 and 200, at the Hawaii Convention Center, Honolulu, Hawaii, U.S.A.
Ms. McGuffy joined Catalent in 2007 with a background in product development, specifically in controlled release solid dosage form development and formulation of poorly soluble compounds. Ms. McGuffy is a registered pharmacist with a Bachelor’s degree in Pharmacy and a Master’s degree in Pharmaceutical Sciences from the University of Zagreb, Croatia. She is a member of the American Association of Pharmaceutical Sciences (AAPS).
Throughout his 30 year career, Mr. Valazza has held various executive positions in product development and technical services with a focus on modified and controlled release solid dosage form applications. Mr. Valazza is a member of a variety of professional organizations including the AAPS (American Association of Pharmaceutical Scientists) and the CRS. He is a recognised leader in the field of controlled release technology and has published articles in various scientific journals and made presentations at numerous industry conferences. Mr. Valazza received a B.S. in Pharmacy from Rutgers University in 1982 and is a registered pharmacist.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com